



2013-06-13

PRESS RELEASE

Oasmia appoints new Vice President Communications

In an effort to strengthen the company's communication with the market, Oasmia has appointed Mikael Widell as a new Vice President Communications. Mikael will be part of the management and will be responsible for the company IR and communications.

Mikael has an extensive experience of communications from the international pharmaceutical industry, AstraZeneca and Biovitrum among others, and from investment companies such as Nordic Capital. The employment begins on July 22.

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

For more information, please contact: Johan Edin, acting Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 14.30 CET on June 13, 2013."